An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

With increasing knowledge on molecular tumour information, precision oncology has
revolutionised the medical field over the past years. Liquid biopsy entails the analysis of …

Circulating tumor-derived DNA (ctDNA) can be used to monitor cancer dynamics
noninvasively. Detection of ctDNA can be challenging in patients with low-volume or …

The use of blood liquid biopsy is being gradually incorporated into the clinical setting of
cancer management. The minimally invasive nature of the usage of cell-free DNA (cfDNA) …

Colon cancer continues to be one of the leading causes of mortality and morbidity
throughout the world despite the availability of reliable screening tools and effective …

Simple Summary In patients with stage III colon cancer, adjuvant chemotherapy with a
fluoropyrimidine combined with oxaliplatin reduces the risk of recurrence and mortality, with …

Simple Summary Stage II colon cancer is defined as an early stage of the tumor disease,
without the involvement of lymph nodes or distant organs. In this group of patients, surgery …

Simple Summary Currently, the treatment for localized colon cancer consists of surgery and,
if the presence of residual cancer cells is suspected, chemotherapy following the surgery …

Colorectal cancer (CRC) is one of the most common gastrointestinal tumors and the second
leading cause of cancer death worldwide. Since traditional biopsies are invasive and do not …

Tumor biopsy is the standard method for cancer diagnosis and provides an important
sample for pathological assessment. With the development of precision medicine, liquid …